01-06.qxp 21.03.

2006 12:49 Seite 31

Scientia Pharmaceutica (Sci. Pharm.) 74, 31-51 (2006) 31

© Österreichische Apotheker-Verlagsgesellschaft m. b. H., Wien, Printed in Austria

,19,752$1',19,92$9$,/$%,/,7<2)0(%(9(5,1(
+<'52&+/25,'(683326,725,(6

%DVPDK1$O'RVVDU\ 2PDLPDK01 $O*RKDU\DQG0DQDO0(O.KDZDDV

'HSDUWPHQWRI3KDUPDFHXWLFV&ROOHJHRI3KDUPDF\.LQJ6DXG8QLYHUVLW\
32%R[5L\DGK6DXGL$UDELD

$EVWUDFW
0HEHYHULQH K\GURFKORULGH VXSSRVLWRULHV ZHUH SUHSDUHG XVLQJ :LWHSVRO +
VXSSRVLWRU\ EDVH 7KH HIIHFW RI GLIIHUHQW FRQFHQWUDWLRQV RI YDULRXV HQKDQFHUV
VXUIDFWDQWV DPLQR DFLGV DQG RVPRWLF PRGLILHUV RQ WKH GUXJ UHOHDVH IRUP WKH
SUHSDUHG VXSSRVLWRULHV ZDV VWXGLHG 7KH UHVXOWV VKRZHG WKDW PHEHYHULQH
K\GURFKORULGHVXSSRVLWRULHVFRQWDLQLQJ %ULM   DQG XUHD  ZHUH VXSHULRU
WRWKHRWKHUIRUPXODWLRQVFRQWDLQLQJWKHWHVWHGHQKDQFHUV7KHVHIRUPXODHVKRZHG
WKH KLJKHVW UHOHDVH UDWHV .   “  PLQ DQG  “  PLQ 
UHVSHFWLYHO\WKDWIROORZHGILUVWRUGHUNLQHWLFVZLWKWRI“PLQDQG“
PLQUHVSHFWLYHO\7KHUHIRUHWKHVHWZRIRUPXODHZLWKWKHFRQWUROVXSSRVLWRULHV
ZHUH VXEMHFWHG WR LQ YLYR VWXG\ LQ DOELQR UDEELWV FRPSDUHG WR WKH FRPPHUFLDO
'XVSDWDOLQŠWDEOHWVDQGLQWUDYHQRXVLQMHFWLRQ
+LJKHU&PD[“QJPOZLWKLQVKRUWHU7PD[“KZDV
REVHUYHGDIWHUUHFWDODGPLQLVWUDWLRQRIWKHFRQWUROVXSSRVLWRULHVFRPSDUHGWRWKDWRI
FRPPHUFLDOO\ DYDLODEOH ILOPFRDWHG WDEOHWV 'XVSDWDOLQŠ ±  PJ $ VLJQLILFDQW
GLIIHUHQFH S” EHWZHHQ WKH DEVROXWH ELRDYDLODELOLW\ RI 'XVSDWDOLQŠ WDEOHWV
 “  DQG FRQWURO VXSSRVLWRULHV  “  ZDV GHWHFWHG
6WDWLVWLFDOO\ S” WKH PHDQ UHVLGHQFH WLPH 057 DIWHU RUDO DGPLQLVWUDWLRQ RI
'XVSDWDOLQŠWDEOHWV“KZDVVLJQLILFDQWO\ORQJHUWKDQWKDWDIWHUWKHUHFWDO
DGPLQLVWUDWLRQRIFRQWUROVXSSRVLWRULHV“KVXSSRVLWRULHVFRQWDLQLQJ
%ULMVKRZHGKLJKHUSODVPDOHYHOVRIWKHGUXJ“QJPOZLWKDQ
01-06.qxp 21.03.2006 12:49 Seite 32

32 Basmah N. Al-Dossary et al.:

DEVROXWH ELRDYDLODELOLW\ RI  “  FRPSDUHG WR  “  IRU
'XVSDWDOLQŠWDEOHWV

.H\ZRUGV
0HEHYHULQHK\GURFKORULGHVXSSRVLWRULHVLQYLWURDQGLQYLYRDYDLODELOLW\HQKDQFHUV
+3/&

,QWURGXFWLRQ
0HEHYHULQHLVDSKHQ\OHWK\ODPLQHGHULYDWLYHRIPHWKR[\EHQ]DPLQH>@,WLV
WKH PRVW SUHVFULEHG SURGXFW FXUUHQWO\ DYDLODEOH IRU WKH WUHDWPHQW RI LUULWDEOH ERZHO
V\QGURPH,%6,WDFWVDVDPXVFXORWURSLFDQWLVSDVPRGLFDJHQWZLWKDGLUHFWDFWLRQ
RQWKHVPRRWKPXVFOHRIWKHJDVWURLQWHVWLQDOWUDFW*,7HVSHFLDOO\RIWKHFRORQ>
@ UHOLHYLQJ VSDVP ZLWKRXW DIIHFWLQJ QRUPDO JXW PRWLOLW\ DQG SRVVHVVLQJ QR
DWURSLQHOLNH DFWLRQ >@ 0RUHRYHU PHEHYHULQH ZDV  WLPHV DV SRWHQW DV
SDSDYHULQLQLQKLELWLQJWKHSHULVWDOWLFUHIOH[RIWKHJXLQHDSLJLOHXPDQGWLPHV
PRUHSRZHUIXOLQLQKLELWLQJVSKLQFWHURI2GGL>@
0HEHYHULQH+&OLVUDSLGO\DQGFRPSOHWHO\DEVRUEHGDIWHURUDODGPLQLVWUDWLRQLQ
WKH IRUP RI WDEOHW RU VXVSHQVLRQ >@ 7KH VSDVPRO\WLF DFWLYLW\ RI WKLV GUXJ ZDV
GHPRQVWUDWHG  KRXUV EXW QRW  KRXUV DIWHU RUDO DGPLQLVWUDWLRQ RI IRUPXODWHG
PHEHYHULQH +&OSRO\FDUERSKLO ORDGHG WDEOHWV LQGLFDWLQJ UDSLG DEVRUSWLRQ DQG
HOLPLQDWLRQ>@+RZHYHUPHEHYHULQHZDVUHSRUWHGWRXQGHUJRUDSLGDQGH[WHQVLYH
ILUVWSDVV PHWDEROLVP IROORZLQJ RUDO DGPLQLVWUDWLRQ >@ 7KH IDFLOH K\GURO\VLV RI
PHEHYHULQHLQIUHVKSODVPDVHHPVDOPRVWDWWULEXWDEOHWRWKHSUHVHQFHRIHVWHUDVHV
>@ 7KH SODVPD FRQFHQWUDWLRQV RI WKH PDLQ PHWDEROLWHV YHUDWULF DFLG >@ DQG
PHEHYHULQHDOFRKRO>@ZHUHGHWHUPLQHGLQKXPDQSODVPDDIWHURUDODGPLQLVWUDWLRQ
RIPHEHYHULQH+&OFRPPHUFLDOWDEOHWV
2Q WKH RWKHU KDQG PHEHYHULQH +&O ZDV IRUPXODWHG DV VXSSRVLWRULHV XVLQJ
GLIIHUHQW W\SHV RI EDVHV DQG ZDV VKRZQ WR EH ZHOO DEVRUEHG UHFWDOO\ YLD H[YLYR
VWXGLHV>@&RQYHQWLRQDOUHFWDOVXSSRVLWRULHVRIPHEHYHULQH+&OIRUWKHUHOLHI
RI DFXWH JDVWURLQWHVWLQDO VSDVP SURGXFHG VDWLVIDFWRU\ VSDVPRO\WLF HIIHFWV WR
01-06.qxp 21.03.2006 12:49 Seite 33

In-vitro and in-vivo availability of mebeverine hydrochloride suppositories 33

VSDVPRJHQ LQGXFHG FRQWUDFWLRQV RQ WKH LVRODWHG JXLQHD SLJ LOHXP >@ ,Q
DGGLWLRQ D VLJQLILFDQW H[WHQGHG VSDVPRO\WLF HIIHFW ZDV REVHUYHG ZLWK WKH
GHYHORSPHQW RI LQ VLWX JHOOLQJ DQG PXFRDGKHVLYH PHEHYHULQH +&O UHFWDO VROXWLRQ
>@ 7KH PHFKDQLVP RI GUXJ DEVRUSWLRQ IURP WKH UHFWXP LV SUREDEO\ QRW GLIIHUHQW
WKDQWKDWLQWKHXSSHUSDUWRIWKH*,7>@
%HFDXVH RI SRRU ELRDYDLODELOLW\ RI RUDO PHEHYHULQH +&O >@ UHFWDO
DGPLQLVWUDWLRQ RI PHEHYHULQH WR DOELQR UDEELWV ZDV HYDOXDWHG 7KH
SKDUPDFRNLQHWLFVDQGWKHH[WHQWRIV\VWHPLFELRDYDLODELOLW\RIPHEHYHULQH+&ODIWHU
RUDODQGUHFWDODGPLQLVWUDWLRQKDYHQRWEHHQFRPSDUHGLQPDQRULQDQLPDOV
,Q WKH SUHVHQW VWXG\ FRQYHQWLRQDO UHFWDO VXSSRVLWRULHV RI PHEHYHULQH +&O ZHUH
SUHSDUHG LQ RUGHU WR DYRLG ILUVWSDVV PHWDEROLVP LQ WKH OLYHU 7KH LQIOXHQFH RI
GLIIHUHQW VXUIDFWDQWV RQ WKH GUXJ UHOHDVH IURP WKH SUHSDUHG VXSSRVLWRULHV ZDV
LQYHVWLJDWHG 7KH EHVW IRUPXODWLRQV ZHUH VXEMHFWHG WR LQ YLYR VWXGLHV LQ DOELQR
UDEELWV 3ODVPD OHYHOV DQG GLIIHUHQW SKDUPDFRNLQHWLF SDUDPHWHUV DIWHU UHFWDO
DGPLQLVWUDWLRQ RI VXSSRVLWRULHV ZHUH GHWHUPLQHG DQG FRPSDUHG ZLWK WKRVH DIWHU
LQWUDYHQRXV,9DQGRUDODGPLQLVWUDWLRQV

([SHULPHQWDO
0DWHULDOV
0HEHYHULQH +&O SRZGHU DQG 'XVSDWDOLQ  FRPPHUFLDO WDEOHW  PJ  ZHUH
REWDLQHG IURP VFLHQWLILF RIILFH RI 'XSKDU %9:HHVS +ROODQG  :LWHSVRO +
1RYHO '\QDPLWH :LWWHQ :HUNH *HUPDQ\ 3RO\VRUEDWH  3RO\VRUEDWH  DQG
7ULWRQ;%3JUDGH$WODV&KHPLFDO,QGXVWULHV:LOPLQJWRQ'(86$%ULM
6RGLXPODXU\OVXOIDWH//\VLQHK\GURFKORULGHDQG8UHD%'+/WG3RROH(QJODQG
,EXSURIHQ SRZGHU LQWHUQDO VWDQGDUG  %RRWV &RPSDQ\ /WG /LYHUSRRO (QJODQG
$FHWRQLWULOH+3/&JUDGH)LVFKHU6FLHQWLILF,QWHUQDWLRQDO&RPSDQ\/HLFHVWHUVKLUH
(QJODQG $FHWLF DFLG  .RFK/LJKW /DERUDWRULHV /WG &ORQEURRN %XFNV (QJODQG
&KORURIRUP+3/&JUDGH%'+/WG 3RROH (QJODQG $OORWKHUFKHPLFDOVZHUHRI
DQDO\WLFDOJUDGHDQGXVHGDVUHFHLYHG
01-06.qxp 21.03.2006 12:49 Seite 34

34 Basmah N. Al-Dossary et al.:

(TXLSPHQWV
'LVVROXWLRQ $SSDUDWXV (UZHND 7\SH '7 )UDQNIXUW *HUPDQ\ &HQWULIXJH
/DERIXJH  +HUDHXV 6HSDWHFK *PE+ *HUPDQ\ 8OWUDVRQLF EDWK ;% *UDQW
,QVWUXPHQWV /WG &DPEULGJH (QJODQG 9RUWH[ :KLUOLPL[HU )LVRQV 6FLHQWLILF
(TXLSPHQW /HLFHVWHUVKLUH (QJODQG 5RWDU\ HYDSRUDWRU 0RGHO 5( %LEE\
6WHULOLQ /WG 6WRQH 6WDIIRUGVKLUH (QJODQG DQG $ +LJK 3HUIRUPDQFH /LTXLG
&KURPDWRJUDSK+3/&V\VWHP-$6&2&RUSRUDWLRQ7RN\R-DSDQZKLFKFRQVLVWV
RI
ƒ $QDQDO\WLFDOSXPSPRGHO38
ƒ $UKHRG\QHLQMHFWRUPRGHO,+,ZLWKȝOORRS
ƒ &ȝ%RQGDSDNFROXPQ:DWHUV$VVRFFP[PP,'SDUWLFOHVL]H
ȝPRSHUDWHGZLWKSUHFROXPQ
ƒ $IOXRUHVFHQFHGHWHFWRUPRGHO)3DQG
ƒ $FKURPDWRJUDSKLF3&EDVHGGDWDVWDWLRQ
0HWKRGV
3UHSDUDWLRQRI0HEHYHULQH +&O6XSSRVLWRULHV
0HEHYHULQH +&O VXSSRVLWRULHV  PJ  J VXSSRVLWRU\ HLWKHU DORQH RU
FRQWDLQLQJGLIIHUHQWFRQFHQWUDWLRQVRIVHOHFWHGHQKDQFHUVVXUIDFWDQWVDPLQRDFLGV
DQG XUHD ZHUH SUHSDUHG DGRSWLQJ WKH PHOWLQJ PHWKRG >@ 'UXJ RU HQKDQFHU
GLVSODFHPHQWYDOXHVLQEDVHXQGHUWHVWZHUHILUVWGHWHUPLQHG>@WKHQWKHDPRXQW
RIWKHEDVHUHTXLUHGZDVFDOFXODWHG7KHSUHSDUHGVXSSRVLWRULHVZHUHNHSWDWR&

'LVVROXWLRQRI0HEHYHULQH+&O6XSSRVLWRULHVDQGFRPPHUFLDOWDEOHWV
'XVSDWDOLQ PJ
'UXJUHOHDVHIRUPGLIIHUHQWVXSSRVLWRU\IRUPXODWLRQVZDVSHUIRUPHGXVLQJWKH
URWDWLQJ EDVNHW GLVVROXWLRQ DSSDUDWXV  7KH GLVVROXWLRQ PHGLXP ZDV  PO RI
SKRVSKDWHEXIIHUS+NHSWDW”R&DQGVWLUUHGDWUSP>@6DPSOHV
ZHUH FROOHFWHG ILOWHUHG VXLWDEO\ GLOXWHG DQG WKHQ DVVD\HG IRU LWV GUXJ FRQWHQW
VSHFWURSKRWRPHWULFDOO\ DW  QP DJDLQVW D EODQN RI D SODFHER VXSSRVLWRU\ 6L[
VXSSRVLWRULHVZHUHXVHGLQHDFKUXQDQGWKHUHVXOWVZHUHDYHUDJHG”6'
01-06.qxp 21.03.2006 12:49 Seite 35

In-vitro and in-vivo availability of mebeverine hydrochloride suppositories 35

'UXJ UHOHDVH IURP WKH FRPPHUFLDO WDEOHWV ZDV SHUIRUPHG LQ  PO RI  1
+&O DW  USP >@  6DPSOHV ZHUH WUHDWHG DV IRU WKH GLVVROXWLRQ WHVW RI
VXSSRVLWRULHVDQGDVVD\HGDWQP6L[WDEOHWVZHUHXVHGDQGWKHUHVXOWVZHUH
DYHUDJHG”6'

3UHSDUDWLRQRILQWUDYHQRXV,9LQMHFWLRQRIPHEHYHULQH+&O
7ZHQW\PJRIWKHGUXJZDVGLVVROYHGLQPOEXIIHUHGQRUPDOVDOLQHVROXWLRQ
S+  7KLV VROXWLRQ ZDV VWHULOL]HG E\ ILOWUDWLRQ WHFKQLTXH WKURXJK D  ȝP
PHPEUDQHILOWHUXQGHUDVHSWLFFRQGLWLRQV

,QYLYRVWXG\GHVLJQ

)RXU PDOH DOELQR UDEELWV ZHLJKLQJ  NJ ZHUH XVHG LQ WKLV VWXG\  7KH
UDEELWVZHUHIDVWHGZDWHUZDVDOORZHGDGOLELWXPIRUKRXUVSULRUWRLQLWLDWLRQRI
WKHVWXG\)RU,9DGPLQLVWUDWLRQDGRVHRIPJRIWKHGUXJZDVLQMHFWHGLQWRWKH
HDUYHLQRIWKHUDEELWV)RURUDODGPLQLVWUDWLRQDGRVHRIFUXVKHGFRPPHUFLDOWDEOHW
HTXLYDOHQWWRPJRIWKHGUXJZDVDGPLQLVWHUHGLQDVOXUU\IRUPGLUHFWO\LQWRWKH
VWRPDFK E\ RUDO LQWXEDWLRQ 7KH IRUPXODWHG VXSSRVLWRULHV ZHUH FXW ORQJLWXGLQDOO\
DQG UDEELWV ZHUH WUHDWHG ZLWK RQH KDOI FRQWDLQLQJ  PJ RI WKH GUXJ  7KH
VXSSRVLWRU\ZDVLQVHUWHGLQWRWKHUHFWXPXVLQJDJODVVLQMHFWRUDWDERXWFPGHSWK
IURP WKH DQXV  7KHQ WKH DQXV ZDV FORVHG ZLWK DQ DGKHVLYH WDSH WR SUHYHQW
OHDNDJH7KHRUGHURIWKHDGPLQLVWUDWLRQRIWKHVHGRVDJHIRUPVZDVGHVLJQHGZLWK
/DWLQVTXDUHPHWKRG$WOHDVWRQHZHHNZDVKRXWSHULRGZDVDOORZHGEHWZHHQWKH
VXFFHVVLYHGRVLQJ
%ORRGVDPSOHVPOZHUHZLWKGUDZQLQWRKHSDULQL]HGYDFXWDLQHUWXEHVXVLQJ
DQ LPSODQWHG FDQQXOD LQ PDUJLQDO HDU YHLQ SULRU WR DQG DW VSHFLILHG WLPH LQWHUYDOV
IROORZLQJ GUXJ DGPLQLVWUDWLRQ 7KH EORRG VDPSOHV ZHUH LPPHGLDWHO\ FHQWULIXJHG DW
 USP IRU  PLQXWHV DQG WKH SODVPD ZDV DVSLUDWHGDQG H[WUDFWHG LPPHGLDWHO\
IRUVXEVHTXHQWDVVD\
$VVD\PHWKRGRIPHEHYHULQHK\GURFKORULGHLQUDEELWSODVPD
3ODVPD VDPSOHV ZHUH DQDO\]HG IRU WKH GUXJ XVLQJ D UHSRUWHG +3/& PHWKRG
>@
01-06.qxp 21.03.2006 12:49 Seite 36

36 Basmah N. Al-Dossary et al.:

6WDQGDUGFXUYHRIPHEHYHULQHLQUDEELWSODVPD
'UXJIUHHUDEELWSODVPDPOZDVVSLNHGZLWKGLIIHUHQWDOLTXRWVRIDTXHRXV
VWDQGDUGVROXWLRQRIPHEHYHULQH+&OLQ RUGHUWRREWDLQPHEHYHULQHFRQFHQWUDWLRQV
LQ WKH UDQJH EHWZHHQ    QJPO 7KHQ ,EXSURIHQ VROXWLRQ LQ PHWKDQRO ZDV
DGGHG WR HDFK WXEH DV WKH LQWHUQDO VWDQGDUG 7KH WXEHV ZHUH WUHDWHG DV UHSRUWHG
>@7KHOLQHDUUHJUHVVLRQHTXDWLRQRIWKHFDOLEUDWLRQFXUYHFRQVWUXFWHGLQWKHVDPH
GD\ ZDV XVHG WR FDOFXODWH WKH GUXJ FRQFHQWUDWLRQ LQ UDEELW SODVPD VDPSOHV
FRQWDLQLQJXQNQRZQFRQFHQWUDWLRQVRIWKHGUXJ
9DOLGDWLRQRIWKHDVVD\PHWKRG
7KH DVVD\ PHWKRG XWLOL]HG ZDV YDOLGDWHG IRU WKH UHSURGXFLELOLW\ LQWUD DQG
LQWHUGD\VDFFXUDF\DVZHOODVWKHSHUFHQWDVVD\UHFRYHU\>@
3KDUPDFRNLQHWLFSDUDPHWHUV
)ROORZLQJ,9DGPLQLVWUDWLRQWKHSODVPDOHYHOGDWDREWDLQHGIURPIRXUDOELQR
UDEELWV ZHUH EHVW ILWWHG WR RQH FRPSDUWPHQW PRGHO XVLQJ 5675,3 FRPSXWHU
SURJUDPYHUVLRQ7KHDUHDXQGHUWKHSODVPDPHEHYHULQH+&OFRQFHQWUDWLRQ±
WLPHFXUYHIURPWLPHWRg$8&gZDVFDOFXODWHGIURPWKHHTXDWLRQ$8&g
 &SR.HO  $OO SKDUPDFRNLQHWLF SUDUDPHWHUV ZHUH FDOFXODWHG >@ DQG H[SUHVVHG
DV PHDQ ” VWDQGDUG GHYLDWLRQ RI WKH PHDQV PHDQ ” 6'0 IROORZLQJ RUDO DQG
UHFWDODGPLQLVWUDWLRQV
6WDWLVWLFDO$QDO\VLV
7KHGLIIHUHQFHLQWKHDYDLODELOLW\RIPHEHYHULQH+&OIURPGLIIHUHQWVXSSRVLWRU\
IRUPXODWLRQV ZDV HYDOXDWHG XVLQJ DQDO\VLV RI YDULDQFH $129$ WHVW RQ FRPSXWHU
0LQLWDESURJUDPYHUVLRQ'LIIHUHQFHVZHUHFRQVLGHUHGVLJQLILFDQWDWSq
)LVKHU¶V /HDVW 6LJQLILFDQW 'LIIHUHQFH /6' ZDV XVHG WR UHYHDO DQ\ VLJQLILFDQW
GLIIHUHQFHEHWZHHQWZRIRUPXODWLRQV
01-06.qxp 21.03.2006 12:49 Seite 37

In-vitro and in-vivo availability of mebeverine hydrochloride suppositories 37

5HVXOWVDQGGLVFXVVLRQ
,QYLWURUHOHDVHFKDUDFWHULVWLFVRIPHEHYHULQH+&OIURPWDEOHWVDQG
IRUPXODWHGVXSSRVLWRULHV
.LQHWLF DQDO\VLV >@ RI WKH UHOHDVH GDWD RI PHEHYHULQH +&O IURP ERWK WKH
FRPPHUFLDO WDEOHWV DQG IRUPXODWHG :LWHSVRO + VXSSRVLWRULHV 7DEOH  UHYHDOHG
WKDWWKHUHOHDVHRIPHEHYHULQH+&OIURPFRPPHUFLDOWDEOHWVIROORZHG]HURRUGHU

7DEOH.LQHWLF$QDO\VLVRIWKH,Q9LWUR5HOHDVH'DWDRI0HEHYHULQH+&O)URPWKH
&RPPHUFLDO'XVSDWDOLQ 7DEOHWVDQG)RUPXODWLRQVRI:LWHSVRO+6XSSRVLWRULHV
&RQWDLQLQJ'LIIHUHQW7\SHV$QG&RQFHQWUDWLRQVRI6XUIDFWDQWV

%HVW)LWWHG
&RUUHODWLRQ
)RUPXOD 0RGHO 6ORSH 5HOHDVH .“6' W “6'
FRHIILFLHQW
2UGHU
  D
'XVSDWDOLQ =HUR    
7DEOHWV )LUVW   =HUR “ “
PJ +LJXFKL    
:LWHSVRO+ =HUR   E 
6XSSRVLWRULHV )LUVW   )LUVW “ “
FRQWURO +LJXFKL    
E
:LW+ =HUR    
3RO\VRUEDWH )LUVW   )LUVW “ “
+/%  +LJXFKL    
E
:LW+ =HUR   )LUVW  
3RO\VRUEDWH )LUVW   “ “
+LJXFKL    
E
:LW+ =HUR    
3RO\VRUEDWH )LUVW   )LUVW “ “
+LJXFKL    
E
:LW+ =HUR    
3RO\VRUEDWH )LUVW   )LUVW “ “
+/%  +LJXFKL    
E
:LW+ =HUR    
3RO\VRUEDWH )LUVW   )LUVW “ “
+LJXFKL    
E
:LW+ =HUR    
3RO\VRUEDWH )LUVW   )LUVW “ “
+LJXFKL    
E
:LW+ =HUR   )LUVW  
%ULM )LUVW   “ “
+/%  +LJXFKL    
E
:LW+ =HUR    
%ULM )LUVW   )LUVW “ “
+LJXFKL    
E
:LW+ =HUR    
%ULM )LUVW   )LUVW “ “
+LJXFKL    
:LW+ =HUR   E 
7ULWRQ; )LUVW   )LUVW “ “
+/%  +LJXFKL    
:LW+ =HUR   E 
7ULWRQ; )LUVW   )LUVW “ “
+LJXFKL    
01-06.qxp 21.03.2006 12:49 Seite 38

38 Basmah N. Al-Dossary et al.:

:LW+ =HUR   E 

7ULWRQ; )LUVW   )LUVW “ “
+LJXFKL    
:LW+  =HUR   E 
6RGODXU\OVXOIDWH )LUVW   )LUVW “ “
+/%  +LJXFKL    
E
:LW+  =HUR    
6RGODXU\OVXOIDWH )LUVW   )LUVW “ “
+LJXFKL    
:LW+  =HUR   E 
6RGODXU\OVXOIDWH )LUVW   )LUVW “ “
+LJXFKL    
6'6WDQGDUGGHYLDWLRQ W7LPHPLQDWZKLFKRIWKHGUXJLVUHOHDVHG =HURRUGHUUHOHDVHUDWHFRQVWDQWPJPOPLQ
D

E
)LUVWRUGHUUHOHDVHUDWHFRQVWDQWPLQ

NLQHWLFVU ZKLOHWKHUHOHDVHRIWKHGUXJIURPWKHIRUPXODWHG:LWHSVRO+

VXSSRVLWRULHVIROORZHGILUVWRUGHUNLQHWLFVU 
7KHUHOHDVHUDWHRIPHEHYHULQH+&OIURPGXVSDWDOLQ  WDEOHWVLVVLJQLILFDQWO\S
qORZHUWKDQWKDWIURPWKHIRUPXODWHGVXSSRVLWRULHV7DEOHDVLQGLFDWHGE\
WKHLU YDOXH RI WKH WLPH UHTXLUHG IRU  RI WKH GUXJ WR EH UHOHDVHG W +LJKHU
UHOHDVH UDWH RI WKH GUXJ IURP :LWHSVRO + VXSSRVLWRULHV FRXOG EH GXH WR WKH
SUHVHQFH RI HPXOVLI\LQJ DJHQW JO\FHU\O PRQRVWHDUDWH LQ WKLV EDVH ZKLFK ZLOO
IDFLOLWDWHWKHGLVSHUVLRQRIWKHPHGLFDPHQWLQWRWKHVXUURXQGLQJPHGLXP0RUHRYHU
PHEHYHULQH+&OEHLQJDK\GURSKLOLFGUXJKDVORZDIILQLW\IRUWKHQRQSRODUSRUWLRQRI
WKH IDWW\ EDVH 'UXJ PROHFXOHV WKHQ ZHUH ZHDNO\ KHOG E\ WKH EDVH PROHFXOHV
OHDGLQJWRUDSLGUHOHDVHRIWKHGUXJ>@
(IIHFWRIWKH$GGLWLRQRI'LIIHUHQW(QKDQFHUV
6XUIDFWDQWV

7KH UHOHDVH UDWH RI WKH GUXJ IURP DOO VXSSRVLWRU\ IRUPXODWLRQV FRQWDLQLQJ
VXUIDFWDQWVZDVLQFUHDVHGZLWKLQFUHDVLQJ WKH FRQFHQWUDWLRQ RI VXUIDFWDQWV )LJXUH
7KLVHQKDQFHPHQWZDVREVHUYHGPRUHFOHDUO\GXULQJWKHILUVWPLQXWHVRIWKH
UHOHDVHWLPHSHULRG+RZHYHUWKHHQKDQFLQJHIIHFWVRI GLIIHUHQWVXUIDFWDQWVZHUH
FRPSDUDEOHDIWHUPLQXWHVDWDOOWKHWHVWHGFRQFHQWUDWLRQV
6XSSRVLWRULHV FRQWDLQLQJ %ULM  VKRZHG IDVWHU UHOHDVH UDWHV RI WKH GUXJ
FRPSDUHGWRVXSSRVLWRULHVFRQWDLQLQJSRO\VRUEDWHRUSRO\VRUEDWH7DEOH
7KLVFRXOGEHDWWULEXWHGWRWKHFKHPLFDOFRPSRVLWLRQRIWKHVXUIDFWDQWDQGWKHW\SH
01-06.qxp 21.03.2006 12:49 Seite 39

In-vitro and in-vivo availability of mebeverine hydrochloride suppositories 39

RIOLQNDJHSUHVHQW>@,QWKLVUHVSHFWWKHHWKHUW\SHVXUIDFWDQW%ULMLVEHWWHU

WKDQ WKH HWKHUHVWHU W\SH VXUIDFWDQWV SRO\VRUEDWHV  $OVR WKH QDWXUH RI WKH IDWW\
DOFRKRO RU IDWW\ DFLG FKDLQ WKDW LV SUHVHQW LQ WKH VXUIDFWDQW PROHFXOH DIIHFWV GUXJ
UHOHDVH >@ 7KXV ODXU\O DOFRKRO %ULM  LV EHWWHU WKDQ PRQRODXUDWH SRO\VRUEDWH
DQGPRQRROHDWHSRO\VRUEDWH7KLVHIIHFWKDGEHHQVLPLODUO\REVHUYHGIRU
R[\SKHQEXWD]RQHUHOHDVHIURP:LWHSVRO+VXSSRVLWRULHV>@+RZHYHU%ULM
KDGVLJQLILFDQWO\UHWDUGHGWKHUHOHDVHRIWLDSURIHQLFDFLGIURPVXSSRVLWRULHV>@



FRQWURO   


 5HOHDVHGDIWHU  P LQXWHV










7ULWRQ; 3RO\VRUEDWH 3RO\VRUEDWH %ULM 6RGLXP/DXU\O
6XOIDWH

)LJ,QYLWURUHOHDVHRIPHEHYHULQH+&ODIWHUPLQXWHVIURP:LWHSVRO+

VXSSRVLWRULHVFRQWDLQLQJGLIIHUHQWFRQFHQWUDWLRQVRIVXUIDFWDQWVLQSKRVSKDWHEXIIHUS+
DW“ R&

7KH HQKDQFHPHQW RI WKH UHOHDVH UDWH SURGXFHG E\ SRO\VRUEDWH  ZDV PRUH
WKDQWKDWSURGXFHGE\SRO\VRUEDWH7KLVFRXOGEHH[SODLQHGRQWKHEDVLVRIWKH
VWUXFWXUHDQG+/%YDOXHVDVZHOODVWKHVL]HDQGQXPEHURIPLFHOODUDJJUHJDWHVRI
WKHVXUIDFWDQWZKLFKLQFUHDVHZKHQWKHOHQJWKRILWVOLSRSKLOLFFKDLQEHFRPHVORQJHU
>@3RO\VRUEDWHDQGFRQWDLQWKHVDPHK\GURSKLOLFFKDLQPRORIHWK\OHQH
01-06.qxp 21.03.2006 12:49 Seite 40

40 Basmah N. Al-Dossary et al.:

R[LGHSHUPRORIVRUELWRODQGWKHGLIIHUHQFHEHWZHHQWKHLUHQKDQFLQJDFWLYLWLHVRQ
WKHUHOHDVHRIPHEHYHULQH+&OZDVGXHWRWKHLUOLSRSKLOLFFKDLQ3RO\VRUEDWHLV
DQROHLFHVWHU&ZKHUHDVSRO\VRUEDWHLVDODXULFHVWHU& >@0RUHRYHU
SRO\VRUEDWH+/% FRXOGHQKDQFHWKHZHWWLQJRIWKHEDVHE\UHGXFLQJWKH
LQWHUIDFLDO WHQVLRQ EHWZHHQ WKH EDVH DQG WKH VXUURXQGLQJ IOXLG PRUH WKDQ
SRO\VRUEDWH+/% DQGWKHUHIRUHKHOSVWKHIORZRXWRIWKHGUXJPROHFXOHV
IURPWKHLQWHUIDFHWRWKHPHGLXP>@7KLV UHVXOWLVLQDJUHHPHQWZLWKWKDWREWDLQHG
IRUPHFOR]LQH+&OUHOHDVHIURP:LWHSVRO+VXSSRVLWRULHV >@
7ULWRQ ; 2FWR[\QRO  LPSURYHG WKH GLVVROXWLRQ UDWH RI PHEHYHULQH +&O
7DEOH7KLVFRXOGEHGXHWRWKHKLJKHU+/%YDOXHRI7ULWRQ;ZKLFK
FRXOG LQFUHDVH WKH K\GURSKLOLFLW\ RI WKH EDVH DQG IDFLOLWDWH GLVSHUVLRQ RI WKH GUXJ
ZLWKLQ WKH VXUURXQGLQJ IOXLGV >@ 6LPLODU HIIHFW ZDV REVHUYHG RQ GLVVROXWLRQ RI
FDUEDPD]HSLQH>@
7KH DGGLWLRQ RI VRGLXP ODXU\O VXOIDWH LRQLF VXUIDFWDQW VOLJKWO\ HQKDQFHG WKH
UHOHDVH UDWH RI WKH GUXJ IURP VXSSRVLWRULHV FRPSDUHG WR RWKHU WHVWHG VXUIDFWDQWV
6OLJKW HIIHFW RI VRGLXP ODXU\O VXOIDWH RQ WKH UHOHDVH UDWH ZDV DOVR REVHUYHG ZLWK
LQGRPHWKDFLQ VXSSRVLWRULHV >@ 7KHUHIRUH LW DSSHDUV WKDW WKH HQKDQFLQJ
SURSHUWLHVRIWKHQRQLRQLFVXUIDFWDQWVDUHJUHDWHUWKDQWKDW SURGXFHGE\WKHLRQLF
W\SH7DEOH
$ VLJQLILFDQW GLIIHUHQFH S q  EHWZHHQ GLIIHUHQW W\SHV DQGRU
FRQFHQWUDWLRQVRIWKHWHVWHGVXUIDFWDQWVZDVUHYHDOHGE\WKHWZRZD\$129$
$PLQR$FLG//\VLQH+&O
7KHUHOHDVHUDWHRIPHEHYHULQH+&OIURPVXSSRVLWRULHVZDVLQFUHDVHGE\WKH
DGGLWLRQ RI /O\VLQH +&O )LJXUH  7DEOH  7KLV PD\ EH GXH WR UHGXFWLRQ RI WKH
PHOWLQJ UDQJH DQG GLVLQWHJUDWLRQ WLPH RI :LWHSVRO +EDVHG VXSSRVLWRULHV >@
ZKLFKFRXOGUHIOHFWEHWWHUVSUHDGLQJRIWKHVXSSRVLWRU\EDVHDQGKHQFHLPSURYHWKH
GUXJUHOHDVH+RZHYHUORZHUUHOHDVHUDWHFRQVWDQWSURGXFHGXSRQWKHDGGLWLRQRI
ZZ/O\VLQH+&O7DEOHFRPSDUHGWRDQGZZFRQFHQWUDWLRQV
FRXOGEHDWWULEXWHGWRWKHSRVVLEOHIRUPDWLRQRIDOHVVVROXEOHPHEHYHULQHO\VLQDWH
FRPSOH[ >@
01-06.qxp 21.03.2006 12:49 Seite 41

In-vitro and in-vivo availability of mebeverine hydrochloride suppositories 41

2VPRWLF0RGLILHU8UHD
6LJQLILFDQW LQFUHDVH S q  LQ WKH UHOHDVH UDWH RI PHEHYHULQH +&O IURP
VXSSRVLWRULHVREVHUYHGE\DGGLWLRQRIXUHD)LJXUH7DEOHPD\EHDWWULEXWHGWR
WKHSRUH±IRUPLQJDELOLW\RIXUHD>@8UHDZDVUHSRUWHGWRLQFUHDVHWKHQXPEHURI
³VXEPLFURQYRLGV´UHVXOWLQJLQDPRUHSRURXVSHUPHDEOHVWUXFWXUHIURPZKLFKWKH
GUXJ ZDV UHOHDVHG >@  $OVR VLQFH XUHD LV D KLJKO\ VROXEOH VXEVWDQFH WKXV WKH






GUXJUHOHDVHG




ZLW+FRQWURO
O\VLQH+&O
 O\VLQH+&O
O\VLQH+&O


     
7LPHPLQ

)LJ,QYLWURUHOHDVHRIPHEHYHULQH+&OIURP:LWHSVRO+VXSSRVLWRULHVFRQWDLQLQJ
GLIIHUHQWFRQFHQWUDWLRQVRI/O\VLQH+&OLQSKRVSKDWHEXIIHUS+DW“R&
01-06.qxp 21.03.2006 12:49 Seite 42

42 Basmah N. Al-Dossary et al.:

7DEOH.LQHWLF$QDO\VLVRIWKH,Q9LWUR5HOHDVH'DWDRI0HEHYHULQH+&O)URP:LWHSVRO
+6XSSRVLWRULHV&RQWDLQLQJ'LIIHUHQW&RQFHQWUDWLRQVRI//\VLQH+&ODQG8UHD

%HVW)LWWHG
&RUUHODWLRQ
)RUPXOD 0RGHO 6ORSH 5HOHDVH .‚“6' W “6'
FRHIILFLHQW
2UGHU
:LWHSVRO+ =HUR    
6XSSRVLWRULHV )LUVW   )LUVW “ “
FRQWURO +LJXFKL    
:LW+ =HUR    
 )LUVW   )LUVW “ “
//\VLQH+&O +LJXFKL    
:LW+ =HUR    
 )LUVW   )LUVW “ “
//\VLQH+&O +LJXFKL    
:LW+ =HUR    
 )LUVW   )LUVW “ “
//\VLQH+&O +LJXFKL    
:LW+ =HUR    
8UHD )LUVW   )LUVW “ “
+LJXFKL    
:LW+ =HUR    
8UHD )LUVW   )LUVW “ “
+LJXFKL    
:LW+ =HUR    
8UHD )LUVW   )LUVW “ “
+LJXFKL    

‚
)LUVWRUGHUUHOHDVHUDWHFRQVWDQWPLQ 6'6WDQGDUGGHYLDWLRQ W7LPH PLQDWZKLFKRIWKHGUXJLVUHOHDVHG

LQWHUQDOSUHVVXUHSURGXFHGE\WKHHQWU\RIZDWHUFRXOGIRUFHWKHGUXJVROXWLRQRXWRI
WKHVXSSRVLWRU\RVPRWLFHIIHFW>@

7KH HQKDQFLQJ HIIHFW REVHUYHG ZLWK WKH DGGLWLRQ RI  XUHD EHVLGHV EHLQJ
FRPSDWLEOH ZLWK ERG\ IOXLGV ZDUUDQWV LQYLYR HYDOXDWLRQ RI WKLV IRUPXOD $OVR
VXSSRVLWRULHVFRQWDLQLQJ%ULMZHUHVXSHULRUWRRWKHUIRUPXODWLRQVFRQWDLQLQJ
VXUIDFWDQWV RU DPLQR DFLG 7KHUHIRUH WKLV IRUPXOD ZDV DOVR VXEMHFWHG WR LQYLYR
HYDOXDWLRQ
01-06.qxp 21.03.2006 12:49 Seite 43

In-vitro and in-vivo availability of mebeverine hydrochloride suppositories 43






GUXJUHOHDVHG



 :LWHSVRO+FRQWURO
XUHD
 XUHD
XUHD


     
7LPHPLQ

)LJ,QYLWURUHOHDVHRIPHEHYHULQH+&OIURP:LWHSVRO+VXSSRVLWRULHVFRQWDLQLQJ
GLIIHUHQWFRQFHQWUDWLRQVRIXUHDLQSKRVSKDWHEXIIHUS+DW“R&

,QYLYR(YDOXDWLRQRI'LIIHUHQW0HEHYHULQH+\GURFKORULGH3UHSDUDWLRQV
7KH DVVD\ PHWKRG XVHG IRU GHWHUPLQDWLRQ RI PHEHYHULQH LQ SODVPD VKRZHG
JRRGDFFXUDF\ZLWKFRHIILFLHQWRIYDULDWLRQUDQJLQJIURPWR7KHDVVD\
UHFRYHU\ GDWD JHQHUDWHG RYHU WKH H[DPLQHG UDQJH RI PHEHYHULQH LQ SODVPD ZHUH
FRQVLVWHQWDQGWKHFRHIILFLHQWVRIYDULDWLRQZHUHZLWKLQRQERWKORZHUDQGXSSHU
HQGVRIWKHDVVD\
7KHVWDQGDUGFDOLEUDWLRQFXUYHRIPHEHYHULQH+&OLQUDEELWSODVPDVKRZHGD
JRRGOLQHDULW\RYHUWKHFRQFHQWUDWLRQUDQJHQJPO
7KHGHFOLQHLQSODVPDFRQFHQWUDWLRQIROORZLQJ,9DGPLQLVWUDWLRQ)LJXUHZDV
EHVWILWWHGWRDRQHFRPSDUWPHQWPRGHOXVLQJ5675,3FRPSXWHUSURJUDPYHUVLRQ
 7KH PHDQ SKDUPDFRNLQHWLF SDUDPHWHUV IROORZLQJ ,9 DGPLQLVWUDWLRQ DUH
SUHVHQWHGLQ7DEOH
01-06.qxp 21.03.2006 12:49 Seite 44

44 Basmah N. Al-Dossary et al.:

7KHUDWHDQGH[WHQWRIDEVRUSWLRQRIWKHGUXJIURPVXSSRVLWRULHVZHUHKLJKHU
WKDQ WKDW IURP WKH RUDO VOXUU\ )LJXUH  +LJKHU YDOXHV RI &PD[ DQG VKRUWHU 7PD[
7DEOH  ZHUH REVHUYHG DIWHU UHFWDO DGPLQLVWUDWLRQ RI FRQWURO VXSSRVLWRULHV
FRPSDUHGWRWKHRUDOURXWH$VLJQLILFDQWGLIIHUHQFHSqEHWZHHQWKHDEVROXWH
ELRDYDLODELOLWLHV RI GXVSDWDOLQ  WDEOHW  ”  DQG FRQWURO VXSSRVLWRULHV
 ”  ZDV GHWHFWHG ,PSURYHG ELRDYDLODELOLW\ IROORZLQJ UHFWDO
DGPLQLVWUDWLRQ RI VXSSRVLWRULHV FRPSDUHG WR RUDO DGPLQLVWUDWLRQV ZDV VLPLODUO\
REVHUYHGZLWKWULPHWKRSULP>@DQGPHUFDSWRSXULQH>@VXSSRVLWRULHV
7KH057DIWHURUDODGPLQLVWUDWLRQ7DEOHZDVVLJQLILFDQWO\ORQJHUSq
WKDQ WKDW DIWHU UHFWDO DGPLQLVWUDWLRQ 7KH ODUJHU YDOXHV RI 7PD[ DQG 057 IROORZLQJ
RUDODGPLQLVWUDWLRQPD\EHGXHWRWKHGHOD\ LQ JDVWULF HPSW\LQJ RI WKH GUXJ ZKLFK
ZLOOVORZWKHUDWHRIGUXJDEVRUSWLRQDQGWKHUHE\GHOD\WKHRQVHWRIWKHWKHUDSHXWLF
HIIHFW>@
,QFRUSRUDWLRQ RI   %ULM  RU  XUHD LQWR VXSSRVLWRULHV UHVXOWHG LQ DQ
LQFUHDVH RI WKH &PD[ YDOXHV DQG D UHGXFWLRQ LQ 7PD[ YDOXHV )LJXUH  7DEOH 
FRPSDUHGWRWKHFRQWUROVXSSRVLWRULHV

7KH HQKDQFLQJ HIIHFW RI %ULM  FRXOG EH DWWULEXWHG WR WKH DELOLW\ RI WKLV QRQ
LRQLFVXUIDFWDQWWRORZHUWKHVXUIDFHWHQVLRQEHWZHHQWKHEDVHDQGWKHVXUURXQGLQJ
UHFWDOIOXLGVWKXVLPSURYLQJWKHZHWWLQJDQGFRQWDFWZLWKWKHHSLWKHOLXPDVZHOODV
GLVWULEXWLRQRIWKHGUXJ >@$OVR%ULME\LWVOLSLGGLVVROYLQJDFWLRQRQWKHUHFWDO
PHPEUDQH > @ PD\ EH FDSDEOH RI PRGLI\LQJ WKH SURSHUWLHV RI ELRORJLFDO
PHPEUDQH E\ VROXELOL]LQJ WKH PHPEUDQH FRPSRQHQWV DQG FDXVLQJ DQ LQFUHDVH RI
SURWHLQUHOHDVHIURPWKHPHPEUDQH0RUHRYHU%ULMZRXOGSUREDEO\LQWHUDFWZLWK
WKH OLSLG SRUWLRQV RI WKH PHPEUDQH WKXV LQFUHDVH WKH SHUPHDELOLW\ RI UHFWDO
PHPEUDQH >@ 7KHVH HIIHFWV ZHUH SURSRVHG IRU WKH LPSURYHG ELRDYDLODELOLW\ RI
FHIR[LWLQ>@IURP:LWHSVRO +VXSSRVLWRULHVFRQWDLQLQJ %ULM
01-06.qxp 21.03.2006 12:49 Seite 45

In-vitro and in-vivo availability of mebeverine hydrochloride suppositories 45



0HDQSODVPDFRQFHQWUDWLRQVQJPO
,9
 2UDOWDEOHW
:LWHSVRO +VXSSFRQWURO
:LWHSVRO+%ULM
:LWHSVRO +XUHD











    
7LPHKU

)LJPHDQSODVPDOHYHOVRIPHEHYHULQH+&OLQUDEELWVIROORZLQJLQWUDYHQRXVRUDO
DGPLQLVWUDWLRQRIFUXVKHGWDEOHWVDQGUHFWDODGPLQLVWUDWLRQRIGLIIHUHQWVXSSRVLWRULHV

7KHLQFUHDVHLQWKHGUXJSODVPDFRQFHQWUDWLRQXSRQWKHDGGLWLRQRIXUHD
)LJXUH7DEOHWR:LWHSVRO+VXSSRVLWRULHVPD\EHGXHWRWKHHIIHFWRIXUHD
DV D SHQHWUDWLRQ HQKDQFHU > @ D NHUDWRO\WLF DJHQW >@ DV ZHOO DV D SURWHLQ
GHQDWXUDQW>@6LPLODUUHVXOWVZHUHVKRZQIRUWKHHQKDQFHPHQWRISHUFXWDQHRXV
DEVRUSWLRQ RI NHWRSURIHQ >@ 7KH IRUPDWLRQ RI ODUJH DQG H[WHQVLYH K\GURSKLOLF
GLIIXVLRQFKDQQHOVZLWKLQWKHVNLQKDVEHHQDOVRSURSRVHGDVDSRVVLEOHPHFKDQLVP
>@0RUHRYHUK\SHUWRQLFXUHDVROXWLRQVZHUHIRXQGWRFDXVHDWUDQVLHQWRSHQLQJ
RI WKH HQGRWKHOLDO MXQFWLRQV RI WKH EORRG EUDLQ EDUULHU UHVXOWLQJ LQ DQ LQFUHDVH RI
SHUPHDELOLW\RIWKHEDUULHU>@

7KHUHIRUH WKH LQFUHDVHG V\VWHPLF DYDLODELOLW\ RI PHEHYHULQH +&O DIWHU UHFWDO
DGPLQLVWUDWLRQ FRXOG EH GXH WR SDUWLDO DYRLGDQFH RI KHSDWLF ILUVWSDVV PHWDEROLVP
>@ 7KH IUDFWLRQ RI WKH GUXJ DYRLGHG ILUVWSDVV PHWDEROLVP DIWHU UHFWDO
DGPLQLVWUDWLRQIQKFDQEHFDOFXODWHGIRUPWKHHTXDWLRQ>@
01-06.qxp 21.03.2006 12:49 Seite 46

46 Basmah N. Al-Dossary et al.:

I Y $8&  'RVH
UHFWDO UHFWDO v $8& RUDO  'RVHRUDO
QK
$8&  'RVH
L Y  L Y  v $8& RUDO  'RVHRUDO

7KH YDOXHV RI  IQK IRU WKH FRQWURO :LWHSVRO + DQG VXSSRVLWRULHV FRQWDLQLQJ  
%ULMRUXUHDZHUHIRXQGWREH””DQG”
UHVSHFWLYHO\
,QFRQFOXVLRQWKHUHVXOWVRIWKLVVWXG\KDYHLPSOLFDWLRQVIRUWKHGHYHORSPHQWRI
VXSSRVLWRULHVDVDUHFWDOGRVDJHIRUPRIPHEHYHULQH+&OWKDWLVQRWFRPPHUFLDOO\
DYDLODEOH 7KH DEVROXWH ELRDYDLODELOLW\ RI PHEHYHULQH +&O IURP WKH FRQWURO
VXSSRVLWRULHVDQGWKRVHFRQWDLQLQJ%ULMDQGXUHDZHUH ”
”DQG”UHVSHFWLYHO\DQG”IRUWKHGUXJLQ
ILOPFRDWHGWDEOHWVLQFRPSDULVRQZLWKWKH,9LQMHFWLRQ
01-06.qxp 21.03.2006 12:49 Seite 47

In-vitro and in-vivo availability of mebeverine hydrochloride suppositories 47

7DEOH0HDQ”6(03KDUPDFRNLQHWLF3DUDPHWHUVRI0HEHYHULQH+&OLQ5DEELWV

)ROORZLQJ ,9 ,QMHFWLRQ 2UDO $GPLQLVWUDWLRQ RI )LOP&RDWHG 7DEOHWV DQG &RQWURO
5HFWDO6XSSRVLWRULHV DQG7KRVH&RQWDLQLQJ'LIIHUHQW(QKDQFHUV

6XSSRVLWRULHV
'XVSDWDOLQ 
3DUDPHWHU ,9,QMHFWLRQ
:LWHSVRO :LW+
)LOP&RDWHG :LW+
+ 
7DEOHWV %ULM
FRQWURO 8UHD

'RVHPJ     

&SRQJPO ”

   


&PD[QJPO   ”  ”  ”  ”

   

7PD[K  ” ” ” ”



$8& ”  ”  ”  ”  ”


WQJKPO      

$8&  ”  ”  ”  ”  ”

     
gQJKPO 

$80& ”  ”  ” ” ”

 
WQJK PO      

$80& ”   ” 

   ” ”  ”
gQJK PO 

057K ” ” ” ” ”



)DEV   ” ” ” ”

  

01-06.qxp 21.03.2006 12:49 Seite 48

48 Basmah N. Al-Dossary et al.:

5HIHUHQFHV

>@ 3URGXFWLQIRUPDWLRQ0HEHYHULQH7UDLQLQJ0DQXDO
'XSKDU%97KH1HWKHUODQGV
>@ 6FKDIIVWHLQ :3DQLMHO0/XWWHFNH.
&RPSDUDWLYH VDIHW\ DQG HIILFDF\ RI WULPHEXWLQH YHUVXV PHEHYHULQH LQ WKH
WUHDWPHQWRILUULWDEOHERZHOV\QGURPH
&XUU7KHU5HV
>@ &RQQHO$0
3K\VLRORJLFDODQGFOLQLFDODVVHVVPHQWRIWKHHIIHFWRIWKHPXVFXORWURSLFDJHQW
PHEHYHULQHRQWKHKXPDQFRORQ
%U0HG-
>@ /LQGHU$6HO]HU+&ODVVHQ9*DQV32IIULQJD25 =ZDJHPDNHUV-0$
3KDUPDFRORJLFDOSURSHUWLHVRIPHEHYHULQHDVPRRWKPXVFOHUHOD[DQW
$UFK,QWHU3KDUPDFRG\Q
>@ 0(3327KH0LGGOH(DVW'UXJ&RPSHQGLXP293+HDOWKFDUH3XEOLFDWLRQV
6$3DULV)UDQFHS
>@ +RVQ\($$O*RKDU\201
5HOHDVH NLQHWLFV DQG DYDLODELOLW\ RI PHEHYHULQH K\GURFKORULGH IURP
SRO\FDUERSKLOORDGHGE\VZHOOLQJ
'UXJ'HY,QG3KDUP
>@ 'LFNLQVRQ5*%DNHU39)UDQNOLQ0(+RRSHU:'
)DFLOH K\GURO\VLV RI PHEHYHULQH LQ YLWUR DQG LQ YLYR QHJOLJLEOH FLUFXODWLQJ
FRQFHQWUDWLRQVRIWKHGUXJDIWHURUDODGPLQLVWUDWLRQ
-3KDUP6FL
>@ :LOOLDPV)0
&OLQLFDOVLJQLILFDQFHRIHVWHUDVHVLQPDQ
&OLQ3KDUPDFRN
>@ .ULVWLQVVRQ-6QRUUDGRWWLU,-RKDQQVRQ0
7KH PHWDEROLVP RI PHEHYHULQH LQ PDQ LGHQWLILFDWLRQ RI XULQDU\ PHWDEROLWHV
E\JDVFKURPDWRJUDSK\PDVVVSHFWURPHWU\
3KDUPDFRO7R[LFRO
>@ 7XOLFK/-5DQGDOO-/.HOP*5:HKPH\HU.5
'HWHUPLQDWLRQ RI WZR PHEHYHULQH PHWDEROLWHV PHEHYHULQH DOFRKRO DQG
GHVPHWK\OPHEHYHULQH DOFRKRO LQ KXPDQ SODVPD E\ D GXDO VWDEOH LVRWRSH
EDVHGJDVFKURPDWRJUDSKLFPDVVVSHFWURSKRPHWULFPHWKRG
-&KURPDWRJ%LRPHG$SSO
>@ $O*RKDU\201)RGD1+
$YDLODELOLW\RIPHEHYHULQHK\GURFKORULGHIURPVXSSRVLWRULHV
3KDUP,QG
>@ +RVQ\($$EG(OKDG\66(O7DKLU.(+
)RUPXODWLRQ LQ YLWUR UHOHDVH DQG H[YLYR VSDVPRO\WLF HIIHFWV RI PHEHYHULQH
K\GURFKORULGHVXSSRVLWRULHVFRQWDLQLQJSRO\FDUERSKLORUSRO\VRUEDWH
,QW-3KDUP
01-06.qxp 21.03.2006 12:49 Seite 49

In-vitro and in-vivo availability of mebeverine hydrochloride suppositories 49

>@ $EGHO+DG\660RUWDGD1$ZDG*$6=DNL107DKD5$
,QYLWURUHOHDVHDQGH[YLYRVSDVPRO\WLFHIIHFWVRIPHEHYHULQHK\GURFKORULGH
IURPUHFWDOVXSSRVLWRULHVFRQWDLQLQJUHOHDVHHQKDQFHUV
(J\S-%LRPHG6FL
>@ $EGHO+DG\660RUWDGD1'$ZDG*$6=DNL107DKD5$
'HYHORSPHQWRILQVLWXJHOOLQJDQGPXFRDGKHVLYHPHEHYHULQHK\GURFKORULGH
VROXWLRQIRUUHFWDODGPLQLVWUDWLRQ
6DXGL3KDUP-
>@ 6FKPLWW0*XHQWHUW7:
,QIOXHQFH RI K\GURSKLOLFLW\ RI VXSSRVLWRU\ EDVHV RQ UHFWDO DEVRUSWLRQ RI
FDUSURIHQDOLSRSKLOLFQRQVWHURLGDODQWLLQIODPPDWRU\GUXJ
-3KDUP6FL
>@ 9LGUDV1-5HLG9(%RKLGDU153ODQNRJLDQQLV0
0HGLFDPHQW UHOHDVH IURP VXSSRVLWRU\ EDVHV , 3K\VLRFKHPLFDO
FKDUDFWHULVWLFVDQGELRDYDLODELOLW\RILQGRPHWKDFLQLQUDEELWV
-3KDUP6FL
>@ ,EUDKLP6(O)DKDP76KDZN\WRXV60RVWDID(
)RUPXODWLRQ UHOHDVH FKDUDFWHULVWLFV DQG HYDOXDWLRQ RI LEXSURIHQ
VXSSRVLWRULHV
,QW-3KDUP
>@ $O$QJDU\$$.KLGU6+$EG(OKDG\66%D\RPL0$0DKURXV *0
6HQVLWLYH KLJK SHUIRUPDQFH OLTXLG FKURPDWRJUDSKLF GHWHUPLQDWLRQ RI
PHEHYHULQHLQSODVPDXVLQJIOXRUHVFHQFHGHWHFWLRQ
$QDO/HWW
>@ 6KDK 9 0LGKD . 'LJKH 6 0F*LOYHUD\ , 6NHOO\ - <DFREL $ /D\ORII 7
9LVZDQDWKDQ&(GJDU&RRN&0F'RZDOO53LWWPDQ.6SHFWRU6
 $QDO\WLFDO PHWKRGV YDOLGDWLRQ %LRDYDLODELOLW\ ELRHTXLYDOHQFH DQG
SKDUPDFRNLQHWLFVWXGLHV
3KDUP5HV
>@ (O6D\HG<$O0HVKDO0$O$QJDU\$$O%DOOD6*RXGD0:
(IIHFWVRIRUDODGPLQLVWUDWLRQRIFKROHVWLSRODQGFKROHVW\UDPLQHRQWKH
SKDUPDFRNLQHWLFVRINHWRSURIHQDGPLQLVWHUHGLQWUDPXVFXODUO\LQPDQ
,QW-3KDUP
>@ +LJXFKL7
0HFKDQLVP RI VXVWDLQHGDFWLRQ PHGLFDWLRQ WKHRUHWLFDO DQDO\VLV RI UDWH RI
UHOHDVHRIVROLGGUXJVGLVSHUVHGLQVROLGPDWULFHV
-3KDUP6FL
>@ ,EUDKLP6$EG(OEDU\$(O6RUDG\+$EG(OPRQHP+
$YDLODEOLW\RIR[\SKHQEXWD]RQHIURPGLIIHUHQWVXSSRVLWRU\IRUPXODWLRQV
3KDUPD]LH+
>@ (O$VVDV\$6ROLPDQ,)DULG6
)RUPXODWLRQDQGELRDYDLODELOLW\RIWLDSURIHQLFDFLGVXSSRVLWRULHV
%XOO)DF3KDUP&DLUR8QLY
01-06.qxp 21.03.2006 12:49 Seite 50

50 Basmah N. Al-Dossary et al.:

>@ )RQWDQ-($UQDXG3&KD\PHLO-&
(QKDQFLQJ SURSHUWLHV RI VXUIDFWDQWV RQ WKH UHOHDVH RI FDUEDPD]HSLQH IURP
VXSSRVLWRULHV
,QW-3KDUP
>@ %HFLUHYLF03HWULFLF9.DOOD\1
,QYLWURUHOHDVHRIPHFOR]LQHK\GURFKORULGHIURPOLSRSKLOLFVXSSRVLWRU\EDVHV
ZLWKRUZLWKRXWWHQVLGHV
3KDUPD]LH+
>@ $PPDU+2PDU6
6ROXELOL]DWLRQRIFDUEDPD]HSLQHE\QRQLRQLFVXUIDFWDQWV
3KDUPD]LH
>@ 2WKPDQ60XWL+
7KH HIIHFW RI EDVHV DQG IRUPXODWLRQ RQ WKH UHOHDVH RI LQGRPHWKDFLQ IURP
VXSSRVLWRULHV
'UXJ'HY,QG3KDUP
>@ +DPPRXGD<(.DVLP1$1DGD$+
)RUPXODWLRQDQGLQYLWURHYDOXDWLRQRIYHUDSDPLO+&OVXSSRVLWRULHV
,QW-3KDUP
>@ $SSHO/=HQWQHU*
8VH RI PRGLILHG HWK\OFHOOXORVH ODWWLFHV IRU PLFURSRURXV FRDWLQJ RI RVPRWLF
WDEOHWV
3KDUP5HV
>@ *LEDOGL0
3URORQJHG5HOHDVH0HGLFDWLRQ
,Q %LRSKDUPDFHXWLFV DQG &OLQLFDO 3KDUPDFRNLQHWLFVWK HGLWLRQ /HD
)HELJHU3KLODGLOSKLD3HQQV\OYDQLD86$
>@ 6DOODL-9HUQ\LN$5HJGRQ**RPENRWR61HPHWK-5HJGRQ-5
([SHULHQFHVZLWKWKHUHFWDOXVHRIWULPHWKRSULP
-3KDUP3KDUPDFRO
>@ .DWR<0DWVXVKLWD7<RNR\DPD70RKUL.
(QKDQFHGELRDYDLODELOLW\RIPHUFDSWRSXULQHDIWHUUHFWDODGPLQLQUDWV
3KDUP5HV
>@ 6KDUJHO/<X$
$SSOLHG ELRSKDUPDFHXWLFV DQG SKDUPDFRNLQHWLFV UG HGLWLRQ $SSOHWRQ
&HQWXU\&URIWV1HZ<RUN86$
>@ 1LVKLKDWD77RPLGD+)UHGHULFN*5\WWLQJ++LJXFKL7
&RPSDULVRQ RI WKH HIIHFWV RI VRGLXP VDOLF\ODWH GLVRGLXP HWK\OHQH GLDPLQH
WHWUD DFHWLF DFLG DQG SRO\[\HWK\OHQHODXU\O HWKHU DV DGMXYDQWV IRU WKH
UHFWDODEVRUSWLRQRIVRGLXPFHIR[LWLQ
-3KDUP3KDUPDFRO
>@ 'DYLV66%XUQKDP:5:LOVRQ32
%ULHQ -
8VH RI DGMXYDQWV IRU HQKDQFHPHQW RI UHFWDO DEVRUSWLRQ RI FHIR[LWLQ LQ
KXPDQV
$QWLPLFURELDO$JHQWVDQG&KHPRWKHUDS\
01-06.qxp 21.03.2006 12:49 Seite 51

In-vitro and in-vivo availability of mebeverine hydrochloride suppositories 51

>@ )L[-$*DUGQHU&5
5HFWDO'UXJ'HOLYHU\DYLDEOHDOWHUQDWLYH
3KDUP,QW1RYHPEHU
>@ 1LD]\(
,QIOXHQFH RI ROHLF DFLG DQG RWKHU SHUPHDWLRQ SURPRWHUV RQ WUDQVGHUPDO
GHOLYHU\RIGLK\GURHUJRWDPLQHWKURXJKUDEELWVNLQ
,QW-3KDUP
>@ .LP &.LP -&KL66KLP&
(IIHFW RI IDWW\ DFLGV DQG XUHD RQ WKH SHQHWUDWLRQ RI NHWRSURIHQ WKURXJK UDW
VNLQ
,QW-3KDUP
>@ +DUYH\6
7RSLFDOGUXJV
,Q 5HPLQJWRQ¶V 3KDUPDFHXWLFDO 6FLHQFHV WK (GLWLRQ 0DFN 3XEOLVKLQJ
&RPSDQ\(DVWRQ3HQQV\OYDQLD
>@ %DWHV,
7KHEORRGEUDLQEDUULHUDQGFHQWUDOQHUYRXVV\VWHPGUXJSHQHWUDWLRQ
3KDUP-
>@ 'H%RHU$*0RROHQDDU)GH/HHGH/*%UHLPHU''
5HFWDOGUXJDGPLQLVWUDWLRQ&OLQLFDOSKDUPDFRNLQHWLFFRQVLGHUDWLRQV
&OLQ3KDUPDFRN
>@ 7RNDGD.<RVKLNDZD+0XUDQLVKL6
3DUWLDO DYRLGDQFH RI ILUVWSDVV HOLPLQDWLRQ RI D]DWKLRSULQH LQ UDWV E\ UHFWDO
GRVLQJ
,QW-3KDUP

Received May 10th, 2005

Accepted February 2nd, 2006